cAMPfield Therapeutics launches with $180M Series A to advance oral PDE4B inhibitor prifemilast in inflammatory bowel disease by thaan@22fillmore.com | Jun 18, 2026 | Portfolio News
Lexeo Therapeutics finalizes SUNRISE-FA 2 pivotal trial design for LX2006 gene therapy in Friedreich ataxia cardiomyopathy by thaan@22fillmore.com | Jun 15, 2026 | Portfolio News
Mirum Pharmaceuticals and Incyte report positive pivotal Phase 2 PROGRESS results for zilurgisertib in fibrodysplasia ossificans progressiva by thaan@22fillmore.com | Jun 14, 2026 | Portfolio News
Zenas BioPharma submits Biologics License Application to the FDA for obexelimab in IgG4-related disease by thaan@22fillmore.com | May 28, 2026 | Portfolio News
CG Oncology reports positive first results from the CORE-008 Cohort CX Phase 2 trial of cretostimogene with gemcitabine in high-risk NMIBC by thaan@22fillmore.com | May 15, 2026 | Portfolio News
Ceribell completes commercial launch of seizure monitoring for newborns and children and activates first sites in its delirium detection pilot by thaan@22fillmore.com | May 11, 2026 | Portfolio News
